How did TNDM's revenue and expenses trend in Q4 2024?

Tandem Diabetes Care (TNDM) experienced a notable increase in revenue and a decrease in net loss for Q4 2024, reflecting improved financial performance compared to the previous quarter.

1. **Revenue Growth**: TNDM's revenue for Q4 2024 was $244.0 million, up by 31% from the previous quarter's revenue of $185.62 million. This growth surpasses market expectations, with reported revenue exceeding analyst estimates by 8.9%.
- The company's domestic sales were $171.65 million, up 31.9% year-over-year.
- International sales contributed $72.32 million, marking a 30.5% increase year-over-year.
2. **Net Income Improvement**: The net loss for Q4 2024 was $23.3 million, a significant reduction from the net loss of $38 million in the previous quarter. This indicates a substantial improvement in the company's profitability.
- Adjusted for non-recurring items, the quarterly loss per share was $0.36, which compares favorably to the previous quarter's loss of $0.38 per share.
3. **Operating Expenses**: R&D expenses increased by 21.9% to $51.1 million. This rise reflects the company's continued investment in innovation, which is crucial for long-term growth in the competitive medical equipment industry.
- The adjusted operating loss for Q3 2024 was $26.1 million, a slight improvement from the $31.5 million loss in the previous year.
4. **Gross Margin**: Gross profit for Q4 2024 was $124.6 million, up 38.9% year-over-year. This indicates enhanced operational efficiency and cost management, contributing to the overall financial improvement.
5. **Cash Position**: TNDM exited Q4 2024 with an improved cash position, although specific figures are not provided.

In summary, TNDM's strategic focus on revenue growth and cost management has yielded positive results, with significant improvements in revenue and net income. However, increased R&D spending highlights the need for careful financial planning to sustain long-term growth.